Skip to main content
Clinical Trials/NCT05879692
NCT05879692RecruitingNot Applicable

Response of Irritable Bowel Syndrome to Abdominal Fat Reduction

Cairo University1 site in 1 country60 target enrollmentStarted: May 28, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
60
Locations
1
Primary Endpoint
change in abdominal subcutaneous fat percentage

Study Overview

Brief Summary

The purpose of the study is to find out the response of Irritable Bowel Syndrome (IBS) to abdominal fat reduction in central obese patients using: application of High Intensity Focused Ultrasound (cavitation) on the abdominal region, aerobic exercise and a dietary regimen that will be low in calories (Low Caloric Diet) and low in fermentable oligo-, di-, mono- saccharides and polyols (low-FODMAPs).

Detailed Description

Irritable bowel syndrome is a common functional gastrointestinal (GI) disorder, with a high global prevalence and a strong impact on the quality of life. There is a positive association between irritable bowel syndrome (IBS) and increased BMI and volume of android fat, according to waist circumference.

Central obesity and Irritable Bowel Syndrome (IBS) are common medical conditions with similar etiologic mechanisms. There are several studies considering obesity as the risk factor for (IBS), but limited studies that to evaluate the association between abdominal obesity and the incidence of irritable bowel syndrome (IBS). Establishing such association is important in the management of IBS.

Focused ultra sound cavitation is a noninvasive safe technique for reducing localized subcutaneous adipose tissue by generating molecular vibrations that elevate the local tissue temperature and produce rapid cell necrosis in targeted tissues.

the investigators believe that focused ultrasound cavitation could improve the overall of Irritable Bowel Syndrome severity as a consequence of abdominal fat reduction.

To the best of the investigators' knowledge, there are limited studies to confirm the improvement of irritable bowel syndrome (IBS) as a result of abdominal fat reduction by focused ultrasound cavitation.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
20 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •All patients will be 20-45 years of age.
  • •Both genders will be participated.
  • •sedentary (exercise < 2 times/week).
  • •Body mass index (BMI) will be ranged from 30 to 39.9 kg/m² and their waist circumference ≥ 102 cm for men and ≥ 88 cm for women.
  • •Patients will have the criteria of Irritable Bowel Syndrome (IBS) according to Rome IV Which are: recurrent abdominal pain on average at least one day per week during the previous three months associated with two or more of the following features must fulfill: (1) Pain is related to defecation; (2) Pain associated with a change in frequency of stool; and (3) Pain associated with a change in form or appearance of stool.
  • •mild to moderate Irritable Bowel Syndrome with score of 75- 300 according to the questionnaire of Irritable Bowel Syndrome Severity Scoring System (IBS-SSS).

Exclusion Criteria

  • •• Under 20 or above 45 years of age.
  • •Athletics
  • •Musculoskeletal, Carcinogenic, or kidney diseases, diabetes, hepatitis and cardiac disorders.
  • •Any condition that may prevent the use of the focused ultrasound on the abdominal region such as scarring, hernias or skin diseases in the abdominal area.
  • •Patients with severe Irritable Bowel Syndrome (IBS) or other known organic gastrointestinal disorders rather than IBS including: (1) Fever, Weight loss or Jaundice; (2) Change in the color of stool; (3) Signs of anemia or Thyroid disease; (4) Abdominal mass or Organomegaly; (5) Signs of intestinal obstruction.

Arms & Interventions

study group (Group A)

Experimental

Will consist of 30 cases suffering from mild to moderate Irritable Bowel Syndrome (IBS) with mild to moderate obesity will receive High Intensity Focused Ultrasound (Cavitation), a dietary regimen that combines Low Caloric Diet (LCD) and low (FODMAPs) diet and aerobic exercises with moderate intensity.

Intervention: focused ultrasound (Procedure)

study group (Group A)

Experimental

Will consist of 30 cases suffering from mild to moderate Irritable Bowel Syndrome (IBS) with mild to moderate obesity will receive High Intensity Focused Ultrasound (Cavitation), a dietary regimen that combines Low Caloric Diet (LCD) and low (FODMAPs) diet and aerobic exercises with moderate intensity.

Intervention: Low Caloric Diet (LCD) and a low (FODMAPs) diet (Behavioral)

study group (Group A)

Experimental

Will consist of 30 cases suffering from mild to moderate Irritable Bowel Syndrome (IBS) with mild to moderate obesity will receive High Intensity Focused Ultrasound (Cavitation), a dietary regimen that combines Low Caloric Diet (LCD) and low (FODMAPs) diet and aerobic exercises with moderate intensity.

Intervention: aerobic exercise (Other)

control group (Group B)

Active Comparator

Will consist of 30 cases suffering from mild to moderate Irritable Bowel Syndrome (IBS) with mild to moderate obesity will receive only the same dietary regimen and aerobic exercise that prescribed for group A.

Intervention: Low Caloric Diet (LCD) and a low (FODMAPs) diet (Behavioral)

control group (Group B)

Active Comparator

Will consist of 30 cases suffering from mild to moderate Irritable Bowel Syndrome (IBS) with mild to moderate obesity will receive only the same dietary regimen and aerobic exercise that prescribed for group A.

Intervention: aerobic exercise (Other)

Outcomes

Primary Outcomes

change in abdominal subcutaneous fat percentage

Time Frame: change from baseline abdominal subcutaneous fat percentage at 12 weeks

abdominal subcutaneous fat percentage will be measured by Dual-energy X-ray Absorptiometry (DXA)

change in total body fat percentage

Time Frame: change from baseline total body fat percentage at 12 weeks

total body fat percentage will be measured by Dual-energy X-ray Absorptiometry (DXA)

change in abdominal visceral fat percentage

Time Frame: change from baseline abdominal visceral fat percentage at 12 weeks

abdominal visceral fat percentage will be measured by Dual-energy X-ray Absorptiometry (DXA)

change in Irritable bowel syndrome Severity Scoring system (IBS-SSS)

Time Frame: change from baseline Irritable bowel syndrome Severity Scoring system at 12 weeks

The Irritable bowel syndrome Severity Scoring System (IBS-SSS) questionnaire was validated by Francis et al. in 1997and consists of five questions that measure: (1) abdominal pain severity; (2) frequency (number of days in every 10 days) with abdominal pain; (3) abdominal bloating/distension; (4) satisfaction with bowel habits; (5) IBS-related quality of life (QoL). Each measure is rated from 0 to 100, with total scores ranging from 0 to 500

change in Irritable bowel syndrome-quality of life (IBS-QOL)

Time Frame: change from baseline Irritable bowel syndrome-quality of life at 12 weeks

The Irritable bowel syndrome-quality of life questionnaire (IBS-QOL) consists of 34 items assessing patients' well-being across eight subscales: dysphoria (eight items); interference with activity (seven items); body image (four items); social reaction (four items); health worry (three items); food avoidance (three items); relationships (three items); and sexual (two items)

Secondary Outcomes

  • change in body weight(change from baseline body weight at 12 weeks)
  • change in waist circumference measurement(change from baseline Waist circumference at 12 weeks)
  • change in body mass index(change from baseline body mass index at 12 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Aly Elrashidy

Principal Investigator

Cairo University

Study Sites (1)

Loading locations...

Similar Trials